PRODUCT DETAILS VIEW ALL PRODUCTS

Xanurix Tablet (Febuxostat)

  • Each tablet contains Febuxostat 40 mg
  • For treatment of chronic hyperuricemia in conditions where urate depression has already occurred (including a history, or presence of tophus and /or gouty arthritis).
  • Febuxostat, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid. Febuxostat is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.
  • One tablet, once daily
  • In patients being treated with azathioprine or, mercaptopurine
  • An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including febuxostat,a higher rate of cardiovascular thromboembolic events was observed in patients treated with febuxostat,if liver injury is detected, promptly interrupt febuxostat, do not restart if liver injury is confirmed.
  • There are no adequate and well-controlled studiesin pregnancy, lactation &children safety and effectiveness in this population have not been established.
  • Febuxostat is aXanthine Oxidase inhibitor, use with caution when co-administering febuxostat with theophylline. Co-administration with XO substrate drugs, azathioprine or mercaptopurine could increase plasma concentrations of these drugs resulting in severe toxicity. In vitro studies have shown that febuxostat does not inhibit P450 enzymes CYP1A2, 2C9, 2C19, 2D6, or 3A4 and it also does not induce CYP1A2, 2B6, 2C9, 2C19, or 3A4 at clinically relevant concentrations. As such, pharmacokinetic interactions between febuxostat and drugs metabolized by these CYP enzymes are unlikely.
  • The adverse reactions reported include Liver Function Abnormalities, Nausea, Rash, dizziness, arthralgia.
  • Anti-Hyperuricaemia